

No. PMBI/LTD/DRUG-186/2022

Dated: 13/06/2022

ORDER

Pharmaceuticals and Medical Devices Bureau of India, New Delhi had published a limited e-tender no. PMBI/LTD/DRUG-186/2022 on 05.01.2022 through e-procurement process for supply of DC – 136, Gliclazide Tablets IP 80mg.

2. Where M/s. Bal Pharma Ltd participated in the above-mentioned tender and the firm was issued with the Purchase Order No. 2102006007, 2102006008, 2102006009 & 2102006010 dated 01.02.2022 for Drug Code – 136 (Gliclazide Tablets IP 80mg). However, the firm do not acknowledge the issued purchase Orders and requested to cancel it by giving reason of wrongly quoted rates. The details of rates quoted by the bidder may be seen in the below table: -

Sr. No	Drug Code	Drug Name	Unit Size	Rate per Unit size exclusive of GST (Rs.)	Rate of GST in %	Rate per Unit size inclusive of GST (Rs.)
1	136	Gliclazide Tablets IP 80mg	10's	0.95	12	1.064

3. Accordingly, Pharmaceuticals and Medical Devices Bureau of India issued a Show Cause Notice dated 25.03.2022 to the tenderer informing them about the tender provisions of clause no. 19.H and 27 (A) giving them opportunity to explain their part within 7 days that why following actions shall not be taken against them: -

- Forfeiture of performance security.
- To make alternate purchase from open market or other sources at the risk and cost of the defaulter bidder.
- Consider your bad performance for future dealings and disqualify your firm/company from participating in the tender for the next 2 years.
- Initiate blacklisting of your firm/company.

4. Whereas following the Show Cause Notice dated 25.03.2022, the firm informed about their inability to supply Drug Code 136 as per the issued Purchase Orders at their quoted L1 rates vide letter dated 30.03.2022.

5. In view of the above-mentioned facts, according to the provisions of tender clause 19.H and 27.A the firm is debarred for a period of 2 years to participate in the tender of PMBI for supply of drug i.e., **Drug Code: 136, Gliclazide Tablets IP 80mg** from the date of issuance of this order and liable for forfeiture of performance security deposit i.e., **Rs. 12,191.84/- (Rupees Twelve Thousand One Hundred Ninety-One and Eighty-Four Paise only)** as per tender terms and conditions.

6. The order is without the prejudice to the legal and criminal action to be taken if any, by Pharmaceuticals and Medical Devices Bureau of India, New Delhi in the matter.



Ravi Dadhich, DANICS
Chief Executive Officer
Pharmaceuticals and Medical Devices Bureau of India
New Delhi